ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
100,525.23
-2.09%
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs Yen
156.032
0.02%
Brent Oil
77.035
-0.19%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Enlivex Therapeutics Ltd (ENLV) 銘柄情報

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd (ENLV)

NASDAQ
1.18
-0.01
(-0.84%)
終了 1月27日 6:00AM
15分遅延
1.185
0.005
(0.42%)
取引時間後: 9:59AM
15分遅延

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
1.18
買値
1.05
売値
1.20
出来高
49,289
1.16 日の範囲 1.19
0.8101 52 週間の範囲 4.59
時価総額
24.638M
前日終値
1.19
始値
1.18
時刻
8
@
1.19
最終取引時間
財務取引量
US$ 57,804
VWAP
1.1727
平均取引量 (3 か月)
237,198
発行済株式数
20,880,000
配当利回り
-
PER
-0.85
1 株当たり利益 (EPS)
-1.39
歳入
-
純利益
-29.07M

Enlivex Therapeutics Ltd について

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.enlivex.com
本社
Ness Ziona, Center, Isr
設立
-
Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ENLV. The last closing price for Enlivex Therapeutics was US$1.19. Over the last year, Enlivex Therapeutics shares have traded in a share price range of US$ 0.8101 to US$ 4.59.

Enlivex Therapeutics currently has 20,880,000 shares in issue. The market capitalisation of Enlivex Therapeutics is US$24.85 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.85.

ENLV 最新ニュース

その他のニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年12月11日
Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

2024年12月11日
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年12月3日
Edgar (US Regulatory)

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

2024年12月3日
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年11月30日
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年11月20日
Edgar (US Regulatory)

Enlivex Adopts Bitcoin Treasury Reserve Strategy

Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

2024年11月20日
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

2024年11月15日
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年11月14日
Edgar (US Regulatory)

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

2024年11月14日
GlobeNewswire Inc.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.021.724137931031.161.2051.12553891.17354376CS
4-0.0702-5.615101583751.25021.271.1999091.18773657CS
12-0.2186-15.62991562991.39861.42890.81012371981.21404942CS
26-0.26-18.05555555561.441.750.81011576991.3099572CS
52-1.68-58.74125874132.864.590.81011400011.70420389CS
156-4.02-77.30769230775.28.640.8101762442.60245904CS
260-8.52-87.83505154649.729.40.81011769728.87797429CS

ENLV - Frequently Asked Questions (FAQ)

What is the current Enlivex Therapeutics share price?
The current share price of Enlivex Therapeutics is US$ 1.18
How many Enlivex Therapeutics shares are in issue?
Enlivex Therapeutics has 20,880,000 shares in issue
What is the market cap of Enlivex Therapeutics?
The market capitalisation of Enlivex Therapeutics is USD 24.85M
What is the 1 year trading range for Enlivex Therapeutics share price?
Enlivex Therapeutics has traded in the range of US$ 0.8101 to US$ 4.59 during the past year
What is the PE ratio of Enlivex Therapeutics?
The price to earnings ratio of Enlivex Therapeutics is -0.85
What is the reporting currency for Enlivex Therapeutics?
Enlivex Therapeutics reports financial results in USD
What is the latest annual profit for Enlivex Therapeutics?
The latest annual profit of Enlivex Therapeutics is USD -29.07M
What is the registered address of Enlivex Therapeutics?
The registered address for Enlivex Therapeutics is 14 EINSTEIN STREET, NESS ZIONA, CENTER, 7403618
What is the Enlivex Therapeutics website address?
The website address for Enlivex Therapeutics is www.enlivex.com
Which industry sector does Enlivex Therapeutics operate in?
Enlivex Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

ENLV Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
ENLV
Enlivex Therapeutics
LSE
ZIG
Zigup
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有